Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Wave Life Sciences Ltd. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters span 4 distinct examiners and 3 distinct art units, showing separate examiner assignments alongside some art-unit overlap.
MOORE, JOHN DAVID is the busiest examiner, with 1 pending action. Since the pending matters are not concentrated with one examiner, prosecution planning should preserve matter-level tracking across the portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, JOHN DAVID | 1 | 61.1% | +28.3% |
| CESARE, JOSEPH DAVID | 1 | 0.0% | +0.0% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.8% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.7% | +22.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18174127 | IMMUNOASSAYS FOR DETECTING WILD TYPE HUNTINGTIN PROTEIN AND METHODS OF TREATMENT EMPLOYING SUCH IMMUNOASSAYS | CESARE, JOSEPH DAVID | 70d overdue |
| 18022509 | CELLS AND NON-HUMAN ANIMALS ENGINEERED TO EXPRESS ADAR1 AND USES THEREOF | WILSON, MICHAEL C | 8d overdue |
| 18695348 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | MOORE, JOHN DAVID | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18022509 | CELLS AND NON-HUMAN ANIMALS ENGINEERED TO EXPRESS ADAR1 AND USES THEREOF | WILSON, MICHAEL C | 8d overdue |
| 18695348 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | MOORE, JOHN DAVID | — |
| 17926967 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | VANHORN, ABIGAIL LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| 1675 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18695348 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | MOORE, JOHN DAVID | 1638 | §102§103§112 | Non-Final OA | — | Pending | Mar 25, 2024 |
| 18174127 | IMMUNOASSAYS FOR DETECTING WILD TYPE HUNTINGTIN PROTEIN AND METHODS OF TREATMENT EMPLOYING SUCH IMMUNOASSAYS | CESARE, JOSEPH DAVID | 1675 | §101§103§112 | Final Rejection | 70d overdue | Pending | Feb 24, 2023 |
| 18022509 | CELLS AND NON-HUMAN ANIMALS ENGINEERED TO EXPRESS ADAR1 AND USES THEREOF | WILSON, MICHAEL C | 1638 | §103§112 | Final Rejection | 8d overdue | Pending | Feb 21, 2023 |
| 17926967 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | VANHORN, ABIGAIL LOUISE | 1636 | §103§112DP | Non-Final OA | — | Pending | Nov 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWave Life Sciences Ltd. has 4 pending office actions as of November 2026, spread across 3 art units and 4 examiners.
John David Moore has the most, with 1 of Wave Life Sciences Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.